Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized

详细信息    查看全文

• 作者：Michael E. Farhangian ; William W. Huang ; Steven R. Feldman
• 关键词：Adherence ; Compliance ; Corticosteroids ; Cutaneous lupus erythematosus (CLE) ; Hydroxychloroquine ; Sunscreen ; Systemic lupus erythematosus (SLE) ; Topical medications
• 刊名：Dermatology and Therapy
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：5
• 期：2
• 页码：91-105
• 全文大小：501 KB
• 参考文献：1.Verma SM, Okawa J, Propert KJ, Werth VP. The impact of skin damage due to cutaneous lupus on quality of life. Br J Dermatol. 2014;170(2):315-1.PubMed View Article
  2.Ezra N, Jorizzo J. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin Exp Dermatol. 2012;37(4):327-4.PubMed View Article
  3.Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011;13(4):300-.PubMed Central PubMed View Article
  4.Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-1.PubMed View Article
  5.Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581-.PubMed
  6.Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212-.PubMed View Article
  7.Conlon NP, Edgar JD. Adherence to best practice guidelines in chronic spontaneous urticaria (CSU) improves patient outcome. Eur J Dermatol. 2014;24(3):385-.PubMed
  8.Torrelo A, Ortiz J, Alomar A, Ros S, Pedrosa E, Cuervo J. Health-related quality of life, patient satisfaction, and adherence to treatment in patients with moderate or severe atopic dermatitis on maintenance therapy: the CONDA-SAT study. Actas Dermosifiliogr. 2013;104(5):409-7.PubMed View Article
  9.Zschocke I, Mrowietz U, Karakasili E, Reich K. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(suppl 2):4-.PubMed View Article
  10.Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006;24(5):348-2.PubMed View Article
  11.Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.PubMed View Article
  12.Frances C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012;148(4):479-4.PubMed View Article
  13.Gutmark EL, Lin DQ, Bernstein I, Wang SQ, Chong BF. Sunscreen use in cutaneous lupus erythematosus patients. Br J Dermatol. 2015.
  14.Oliveira-Santos M, Verani JF, Klumb EM, Albuquerque EM. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus. 2011;20(3):320-.PubMed View Article
  15.Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(10):3284-0.PubMed View Article
  16.Ting TV, Kudalkar D, Nelson S, Cortina S, Pendl J, Budhani S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol. 2012;39(1):174-.PubMed View Article
  17.Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):821-.PubMed Central PubMed View Article
  18.Zeller A, Ramseier E, Teagtmeyer A, Battegay E. Patients-self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertens Res. 2008;31(11):2037-3.PubMed View Article
  19.Osterberg L, Blaschke T. Adherence to medication. New Engl J Med. 2005;353(5):487-7.PubMed View Article
  20.Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum. 2002;47(6):630-.PubMed View Article
  21.Nived O, Andersson M, Lindgren M, Malcus-Johnsson P, Nihlberg A, Nived K, et al. Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: a study with a questionnaire. Lupus. 2007;16(9):701-.PubMed View Article
  22.Koneru S, Kocharla L, Higgins GC, Ware A, Passo MH, Farhey YD, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008;14(4):195-01.PubMed
  23.Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum. 2009;61(2):240-.PubMed Central PubMed View Article
  24.Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medic
• 作者单位：Michael E. Farhangian (1)
  William W. Huang (1)
  Steven R. Feldman (2) (3)
  
  1. Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
  2. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA
  3. Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
  
• 刊物主题：Internal Medicine; Dermatology; Plastic Surgery; Oral and Maxillofacial Surgery; Quality of Life Research;
• 出版者：Springer Healthcare
• ISSN：2190-9172

文摘

Introduction Treatment adherence plays a large role in chronic dermatologic diseases and may play an important role in the outcomes of patients with cutaneous lupus erythematosus (CLE). We sought to gauge what is currently known about adherence to topical and oral medications in patients with CLE. Methods A review of MEDLINE was performed using a combination of the phrases “adherence- “compliance- “lupus- and “cutaneous- Studies were hand searched and prospective and cross-sectional studies evaluating medication adherence in patients with CLE and systemic lupus erythematosus (SLE) were included. Results Only two articles explored adherence in patients with CLE, while 17 articles discussed treatment adherence in patients with SLE. Depression was consistently cited as detrimental to adherence. The impact that race, ethnicity, and education has on adherence is unclear. Three studies noted a clear connection between adherence and disease activity, while two others did not. Few studies investigated methods that have improved adherence to treatment which have showed promise. Conclusion Much of what we know about adherence to medication in patients with lupus is limited to SLE. Although cutaneous symptoms are among the most common manifestations of SLE, cutaneous disease is often managed at least in part with topical agents, and adherence to topical treatment was not assessed in any of the articles, though one study investigated sunscreen usage in patients with CLE. Understanding adherence in patients with CLE may help contribute to better CLE treatment outcomes.